OncoCyte Corp (OCX) : Destination Wealth Management has sold out all of its stake in OncoCyte Corp during the most recent quarter, according to the disclosure filed by the company on Apr 20, 2016 with the SEC. The investment management company has sold out 29,657 shares of OncoCyte Corp which is valued at $165,783.
Other Hedge Funds, Including , Creative Planning reduced its stake in OCX by selling 1,750 shares or 84.75% in the most recent quarter. The Hedge Fund company now holds 315 shares of OCX which is valued at $1,733.
Many Wall Street Analysts have commented on OncoCyte Corp. Lake Street Initiated OncoCyte Corp on Mar 24, 2016 to “Buy”, Price Target of the shares are set at $8.
OncoCyte Corporation (OncoCyte) is engaged in developing non-invasive liquid biopsy diagnostic tests in areas of high unmet need in oncology. The Company’s initial focus is confirmatory diagnostics that are used in conjunction with imaging to confirm initial diagnoses. It also focuses on developing screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients health care providers or payers. It operates in the research and development of diagnostic tests for the detection of cancer segment. For some indications it also focuses on pursuing the probability of recurrence of a specific cancer through the development of prognostics or companion diagnostics that help a physician determine which therapy is the optimal treatment for the patient. It is working on diagnostic tests for three types of cancer: lung cancer breast cancer and bladder cancer.